Skip to main
CC
CC logo

Chemours (CC) Stock Forecast & Price Target

Chemours (CC) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Chemours Co is positioned for a positive financial outlook, primarily due to its ability to raise prices for Flex portal and distribution customers, which indicates strong pricing power in the market. Furthermore, the company anticipates improved TiO2 margins by 2025, despite facing near-term challenges from higher raw material costs and sluggish demand in Europe and Asia. Additionally, Chemours's ongoing "Pathway to Thrive" plan is projected to generate over $250 million in incremental run-rate cost savings through 2027, with a significant portion expected to be realized by the end of 2025.

Bears say

Chemours faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from a slowdown in demand for hydrofluorocarbons (HFCs) and hydrofluoroolefins (HFOs) due to regulatory changes, alongside heightened competition in HFO technology. Additionally, new capacity announcements in the TiO2 segment threaten to exacerbate existing weaknesses in pricing and end-market demand, particularly in the housing and automotive sectors. The company is also impacted by weakening global macroeconomic conditions, which further dampen its revenue prospects, especially as it relies heavily on its Titanium Technologies segment for income generation.

Chemours (CC) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Chemours and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Chemours (CC) Forecast

Analysts have given Chemours (CC) a Buy based on their latest research and market trends.

According to 8 analysts, Chemours (CC) has a Buy consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Chemours (CC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.